CPA Releases Comments on Section 232 Investigation of Pharmaceutical Imports

CPA Releases Comments on Section 232 Investigation of Pharmaceutical Imports

As the leading organization advocating for reshoring the generic drug industry, CPA’s submission documents how extreme overreliance on foreign pharmaceutical supplies—especially active pharmaceutical ingredients (APIs) and critical injectable drugs from China and India—poses an urgent threat to U.S. national security and patient safety.

UK and China Tariff Agreements Might be The First and the Last

UK and China Tariff Agreements Might be The First and the Last

This month’s tariff agreements with the United Kingdom and China might end up being the first deal of its kind, and the last. On Friday, President Trump reiterated that the administration could not possibly strike deals with every country, and that tariff announcements would be made over the next two to three weeks.

CPA Expresses Concern over U.S.-UK Trade Framework’s Impact on U.S. Steel Industry

CPA Expresses Concern over U.S.-UK Trade Framework’s Impact on U.S. Steel Industry

While CPA recognizes certain positive elements of the deal — including a historic pivot towards prioritizing tariff revenue as well as industrial protection — it remains concerned about dangerous precedents being set by sacrificing domestic production while pursuing foreign market access.